<DOC>
	<DOC>NCT02781558</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed dose combination (FDC) and SOF/VEL FDC and Ribavirin (RBV) for 12 weeks in participants with chronic genotype 3 HCV infection and compensated cirrhosis.</brief_summary>
	<brief_title>Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Male and nonpregnant/ nonlactating female individuals Individuals with chronic genotype 3 HCV infection and compensated cirrhosis Laboratory values within threshold at screening Individuals with or without HIV1 coinfection Key History of clinically significant illness or any other medical disorder that may interfere with individual's treatment assessment or compliance with the protocol Coinfection with acute hepatitis B virus Known hypersensitivity to study medication Use of any prohibited concomitant medications as within with window before the Day 1 visit. Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>